<DOC>
	<DOC>NCT02456558</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, antiretroviral activity, pharmacokinetics, and pharmacodynamics of an intravenous formulation of deferiprone in HIV-infected subjects.</brief_summary>
	<brief_title>Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects</brief_title>
	<detailed_description>This is a double-blind, placebo-controlled, randomized trial in 30 asymptomatic HIV-positive adults. There are two sequential cohorts, in which subjects will receive either one of 2 doses of deferiprone or placebo twice daily.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>HIV1 positive HIV treatmentnaïve: no previous treatment with a combination antiretroviral therapy (cART) or highly active antiretroviral therapy (HAART) regimen HIV1 RNA &gt; 10,000 copies/mL ALT or AST ≤ 2.0 x upper limit of normal range, and bilirubin within normal range Body mass index (BMI) of 18.5 to 30.0 kg/m^2 Absolute neutrophil count at baseline of ≥1.0 x 10^9/L (black African population only) or ≥1.5 x 10^9/L (all other races) Evidence of AIDSassociated illness, excluding superficial candidiasis CD4+ Tcell count of &lt; 350/mm^3 Positive for active or latent tuberculosis, as determined by the QuantiFERON®TB Gold test Active, serious infections (other than HIV1 infection) within the 30 days prior to screening Positive for hepatitis B surface antigen (HBsAg) and/or hepatitis virus C (HCV) antibodies History or presence of malignancy A serious, unstable chronic illness during the past 3 months before screening A serious, unresolved acute illness at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>antiretroviral drugs</keyword>
	<keyword>deferiprone</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>